Aastrom Acquires Sanofi's Cell Therapy and Regenerative Medicine Business - - BioPharm International

ADVERTISEMENT

Aastrom Acquires Sanofi's Cell Therapy and Regenerative Medicine Business



Aastrom Biosciences, a developer of patient-specific cellular therapies for the treatment of severe diseases and conditions, has completed its acquisition of Sanofi's cell therapy and regenerative medicine (CTRM) business unit. As reported on April 21, 2014, Aastrom paid $4 million in cash and $2.5 million in a promissory note to acquire the CTRM business, which includes three marketed products in the US and Europe, as well as manufacturing and production centers in the US and Denmark.

The three marketed autologous cell therapy products acquired by Aastrom include Carticel, an autologous chondrocyte implant (ACI) product marketed in the US for the treatment and repair of articular cartilage defects in the knee; Epicel, a permanent skin replacement for full-thickness burns greater than or equal to 30% of total body surface area, which is marketed in the US; and MACI, a third-generation ACI product currently marketed in the EU for the treatment of focal chondral defects in the knee.

Source: Aastrom Biosciences

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

PDA Announces Technical Report on Drug Shortages
September 9, 2014
European Commission Approves RoACTEMRA for Treatment of RA
September 9, 2014
DPT Laboratories Acquires Media Pharmaceuticals' Lakewood Facilities
September 5, 2014
Merck KGaA Breaks Ground on Facility in China
September 5, 2014
FDA Releases Guidance Electronic Submission of Lot Distribution Reports
September 5, 2014
Author Guidelines

Click here